Goldman Sachs Downgrades Adeptus Biotechnologies Corp. (ADPT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $26.64 -5.43%
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter downgraded Adeptus Biotechnologies Corp. (NASDAQ: ADPT) from Buy to Neutral with a price target of $63.00 (from $74.00).
For an analyst ratings summary and ratings history on Adeptus Biotechnologies Corp. click here. For more ratings news on Adeptus Biotechnologies Corp. click here.
Shares of Adeptus Biotechnologies Corp. closed at $53.11 yesterday.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Digital Realty Trust (DLR) PT Lowered to $227 at Freedom Broker
- Reddit (RDDT) PT Lowered to $210 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
